This is a list of current Incubator resident companies.
AXOGEN, Inc. is a biomedical company developing products that will allow surgeons to repair and regenerate peripheral nerves more successfully than ever before. Every year in the US, several million people suffer peripheral nerve injuries, a major source of disability that impairs the ability to move muscles or to feel normal sensations. AxoGen, utilizing a seasoned management team with a strong track record, is revolutionizing peripheral nerve procedures based on scientific breakthroughs that reveal the mechanism of axon growth and regeneration.
Contact: Jamie Grooms, CEO, 352.244.5813, jmgrooms@cox.net
www.axogeninc.com
BANYAN BIOMARKERS, INC. is focused on commercializing novel biomarker in vitro diagnostic products to address unmet clinical needs associated with organ injury. Our initial diagnostic products will be used for the detection and monitoring of traumatic brain injury (TBI). Until now, no simple, point-of-care blood test existed for use by physicians in the emergency room or in the hospital to detect the presence and severity of brain trauma. Banyan research has identified unique and proprietary biomarkers present in the patient's blood following injury to the brain. Detecting these biomarkers will provide early indications of brain trauma essential for earlier intervention and management. Banyan’s other development program includes biomarker tests for other injured organs such as heart, liver and lungs.
Contact: Gary Ascani, CEO, 386.462.2481, gascani@banyanbio.com
www.banyanbio.com
BIKAM PHARMACEUTICALS, INC. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company’s founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
Contact: Muzammil Mansuri, CEO, 386.418.1335, mmansuri@jsb-partners.com or David Garvey, VP, Chemistry, dsgconsult@comcast.net
BIOENERGY INTERNATIONAL, LLC, headquartered in Norwell, Massachusetts is a privately held, biotechnology company committed to develop and deliver advanced technologies to produce clean, environmentally beneficial fuels and specialty chemicals from traditional feedstocks and cellulose. BioEnergy currently has under development a pipeline of novel biocatalysts and two 108 million gallon per year ethanol plants which, over time, will utilize its proprietary technologies to produce high value specialty chemicals and renewable fuels.
Contact: Joseph Glas, SVP Research & Development, 781.681.5050.
www.bioenergyllc.com
INTEGRATED PLANT GENETICS, INC. is a development stage biotechnology company in business to develop, produce and license genetic technologies for horticultural, agricultural and food production industries. IPG is developing environmentally sound and sustainable genetic alternatives to make plants resistant to diseases without using costly and toxic chemical pest control. IPG’s unique genetic modification approaches are designed and developed to be safe for human and animal consumption. According to the Grocery Manufacture’s Association, over 70% of the groceries in U.S. shelves are already made with some genetically engineered component. IPG is also the first and only agricultural genetic engineering company in Florida, the second largest agriculture products producing state in the U.S.
Contact: Dean Gabriel, CEO, 386.418.3494, ipg@biotech.ufl.org
www.ipgenetics.com
NANOMEDEX, INC., uses nanotechnology to research and develop novel methods of medical diagnostics and therapeutics. As an initial focus, NanoMedex, Inc. is developing proprietary nanotechnology designed to improve the current formulations of clinically relevant, off patent lipophilic drugs such as propofol, the most frequently used intravenous anesthetic.
Contact: David Cooper, CEO, 386.462.5740, DLCooper12451@hotmail.com
PASTEURIA BIOSCIENCE, INC. is an early-stage agricultural biotechnology company formed to address the world’s largest unmet pest-control problem: plant-parasitic nematodes. Our proprietary technology allows the in-vitro growth and sporulation of Pasteuria penetrans, a naturally-occurring nematode pathogen, for nematode control in crops ranging from high-value ornamentals to agronomic staples.
Contact: David Duncan, President & CEO, 386.462.7587, dduncan@pasteuriabio.com
www.pasteuriabio.com
RFE PHARMA, INC. will provide physicians with innovative somatostatin drugs to treat unmet medical needs in patients suffering from cancer, diabetes, central nervous system (CNS) and gastrointestinal (GI) diseases. The company is developing the world’s first peptidomimetic somatostatin drug products to improve the quality of life in patients who currently rely on expensive, injectable peptide drug medications. A class of high potency drugs has been designed to make the established benefits of somatostatin therapy affordable and widely available. RFE’s broader mission is to extend the scope of somatostatin therapy. Products for chronic application are being tailored for improved management of metastatic cancer, diabetic retinopathy and gastrointestinal disease states. As a new milestone in medicine, the company is pioneering the world’s first CNS active somatostatin diagnostics and drugs for epilepsy and mental health disorders.
Contact: Gideon Shapiro, CSO 386.462.4323, gshapiro@somatocor.com
www.rfepharma.com
SHARKLET TECHNOLOGIES, LLC is a surface technology company that controls the growth of microorganisms through its revolutionary engineered topography, Sharklet™. Inspired by a shark skin pattern, Sharklet™ is the first, non-toxic, eco-friendly product evercreated to truly inhibit or enhance the growth of microorganisms. There are two primary uses for Sharklet – marine and medical industries. In the medical device industry, the Sharklet™ pattern has already shown signs of radically increasing the amount of time it takes for bacterial biofilms to develop. Sharklet is now being tested with human protein conditions present to determine if bacterial biofilm formation can be inhibited for up to 21 days. Contact: Joe Bagan, CEO, 386.418.0078, jbagan@sharklet.com
ST CHARLES PHARMACEUTICALS, INC. is a CNS drug development company exploiting novel approaches to therapeutic intervention by targeting the crossover of signaling pathways for pain and neuro-inflammation. The Company’s lead clinical candidate, SCP-123 (IND Enabling), is efficacious and safe in non-clinical studies, and is one of a series of safer and more potent non-opiod analgesics discovered by our founder, Dr. Nicolas Bazan. SCP’s focus is translating early-stage compounds into clinical candidates. SCP is currently funded by SBIR grants, and is seeking to raise its first round of venture financing.
Contact: Donna Millington, Sr. Research Investigator/Lab Manager, 386.462.7015, dmillington@stcharlespharma.com
www.stcharlespharma.com
XHALE, INC. is developing a line of breath-based devices that will detect the presence and/or concentration of various substances in the blood, replacing many conventional diagnostic tests. Among the first of Xhale’s planned product lines is a breath-based medication adherence device for use in measuring the compliance of patients enrolled in clinical trials. The company’s researchers are also pursuing a device that would replace consumer glucose monitors which currently require diabetics to prick their skin to draw a blood sample. Instead of utilizing blood, Xhale’s glucose monitor would analyze the breath non-invasively for glucose concentration, giving quick, accurate and painless results.
Contact: Richard R. Allen, Chief Executive Officer, 352.371.8488, rallen@xhale.com
www.xhale.com